In a squeaker, FDA AdComm votes for an OK of Cempra’s antibiotic
Cempra $CEMP just barely squeaked through an AdComm review for its proposed new antibiotic solithromycin on Friday, with a slim majority of 7 to 6 casting votes in its favor on the key question of whether the benefits outweighed the obvious toxicity risks associated with their product.
Past safety issues associated with telithromycin (Ketek) clearly weighed on all the members, but with growing resistance to existing antibiotics becoming an ever-growing public health crisis, there were enough ‘yes’ votes to get this one over the line.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.